January 8, 2017 | Clal Biotechnology Industries Ltd. announced today that Neon Therapeutics had completed a $70 million financing round. Following the round, Clal Biotechnology will own 5% of US company Neon. The round was led by Partner Fund Management, together with Inbio, Wellington, Fidelity Ventures, and Nextech Invest. Previous investors Third Rock Ventures and Access Industries also took part. Neon has begun a trial of a vaccination against malaria. Clal Biotechnoloigy was founded in 1998 and is based out of Ramat Gan, Israel.
Related posts
Top European Carmakers To Include Israeli Chipset In New Vehicles
September 18, 2024
Sheba Named As One Of World's Top 10 Smart Hospitals
September 18, 2024
New AI-Powered Robot Specializes In Picking Citrus Fruit
September 17, 2024
Researchers Develop New Early Identification For Parkinson’s
September 16, 2024
Facebook comments